VOR VOR BIOPHARMA INC revenue, earnings and financials
For the quarter ended June 30, 2026, VOR BIOPHARMA INC reported revenue of n/a, net income of −$62.8M and diluted EPS of −$1.16; for the fiscal year ended December 2025 revenue was n/a.
VOR annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$372M, net income −$696M (margin n/a), EPS −$70.50
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$121M, net income −$117M (margin n/a), EPS −$34.03
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$126M, net income −$118M (margin n/a), EPS −$1.75
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$93.4M, net income −$92.1M (margin n/a), EPS −$2.33
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$69.0M, net income −$68.9M (margin n/a), EPS −$2.10
VOR quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$62.8M, EPS −$1.16
- Quarter ended Mar 31, 2026: revenue n/a, net income −$220M, EPS −$5.11
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $1.72B, EPS $307.58
- Quarter ended Sep 30, 2025: revenue n/a, net income −$813M, EPS −$121.63
- Quarter ended Jun 30, 2025: revenue n/a, net income −$1.57B, EPS −$251.24
- Quarter ended Mar 31, 2025: revenue n/a, net income −$32.5M, EPS −$5.21
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$30.7M, EPS −$25.12
- Quarter ended Sep 30, 2024: revenue n/a, net income −$27.6M, EPS −$8.05
- Quarter ended Jun 30, 2024: revenue n/a, net income −$27.8M, EPS −$0.41
- Quarter ended Mar 31, 2024: revenue n/a, net income −$30.8M, EPS −$0.45
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$26.3M, EPS −$0.38
- Quarter ended Sep 30, 2023: revenue n/a, net income −$33.2M, EPS −$0.49
- Quarter ended Jun 30, 2023: revenue n/a, net income −$30.0M, EPS −$0.45
- Quarter ended Mar 31, 2023: revenue n/a, net income −$28.4M, EPS −$0.43
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$23.9M, EPS −$0.51
- Quarter ended Sep 30, 2022: revenue n/a, net income −$23.8M, EPS −$0.63
- Quarter ended Jun 30, 2022: revenue n/a, net income −$21.7M, EPS −$0.58
- Quarter ended Mar 31, 2022: revenue n/a, net income −$22.7M, EPS −$0.61
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$18.3M, EPS −$0.43
- Quarter ended Sep 30, 2021: revenue n/a, net income −$18.6M, EPS −$0.50
VOR cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$143M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$99.7M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$100M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$85.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$69.1M, share buybacks n/a
VOR balance sheet
- Jun 30, 2026: cash $108M, total assets $481M, total liabilities $681M, shareholders' equity −$200M
- Mar 31, 2026: cash $170M, total assets $507M, total liabilities $657M, shareholders' equity −$150M
- Dec 31, 2025: cash $396M, total assets $464M, total liabilities $628M, shareholders' equity −$164M
- Sep 30, 2025: cash $160M, total assets $176M, total liabilities $2.40B, shareholders' equity −$2.23B
- Jun 30, 2025: cash $191M, total assets $205M, total liabilities $1.71B, shareholders' equity −$1.51B
- Mar 31, 2025: cash $50.0M, total assets $109M, total liabilities $43.2M, shareholders' equity $66.1M
- Dec 31, 2024: cash $81.9M, total assets $143M, total liabilities $46.2M, shareholders' equity $96.7M
- Sep 30, 2024: cash $52.8M, total assets $116M, total liabilities $43.0M, shareholders' equity $73.0M
Is VOR profitable?
Yes. VOR BIOPHARMA INC earned $628M over the last four quarters.
What is VOR's EPS?
Diluted earnings per share over the last four quarters were $179.68; −$1.16 in the latest quarter.